Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cazzagon, Nora
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Linerixibat	GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited	Cholestasis	08/27	08/27
NCT05642468: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis	Active, not recruiting	2	18	Europe	Ritivixibat	Albireo, an Ipsen Company	Primary Sclerosing Cholangitis	06/25	06/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT05618145: National Database on Primary Sclerosing Cholangitis (PSC)	Recruiting	N/A	6000	Europe	Clinical information	University of Milano Bicocca	Primary Sclerosing Cholangitis	10/32	10/32
Fabris, Luca
NCT05618145: National Database on Primary Sclerosing Cholangitis (PSC)	Recruiting	N/A	6000	Europe	Clinical information	University of Milano Bicocca	Primary Sclerosing Cholangitis	10/32	10/32

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cazzagon, Nora
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Linerixibat	GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited	Cholestasis	08/27	08/27
NCT05642468: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis	Active, not recruiting	2	18	Europe	Ritivixibat	Albireo, an Ipsen Company	Primary Sclerosing Cholangitis	06/25	06/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT05618145: National Database on Primary Sclerosing Cholangitis (PSC)	Recruiting	N/A	6000	Europe	Clinical information	University of Milano Bicocca	Primary Sclerosing Cholangitis	10/32	10/32
Fabris, Luca
NCT05618145: National Database on Primary Sclerosing Cholangitis (PSC)	Recruiting	N/A	6000	Europe	Clinical information	University of Milano Bicocca	Primary Sclerosing Cholangitis	10/32	10/32